MedTrace Logo

Speckle Tracking Echocardiography as a Tool for Early Diagnosis of Impaired Fetal Growth Twin Pregnancies

NCT05423665 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 360

Last updated 2023-09-26

No results posted yet for this study

Summary

In this project there are 2 time points during the pregnancy included, namely at 21 weeks and 30 weeks of gestation, to measure the predictive values of FGR, strain and strain rate. The fetal growth parameters will be collected at the same time points, to define the growth (differences) throughout gestation of both fetuses. A maternal blood sample will be taken at 21 weeks of gestation to identify the level of exposure to air pollution (black carbon) and the level of biochemical markers of placental dysfunction. Doppler ultrasounds will be used for antenatal identification of placenta insufficiency. At birth, umbilical cord blood and the placenta will be collected. The placenta will be examined, to identify morphological findings which are associated with FGR. The umbilical cord blood and placental biopsy will be used for the level of exposure to air pollution and the level of oxidative stress. One to three days after birth, neonatal strain and strain rate will be measured to define postnatal cardiac remodeling as well as the neonatal blood pressure as cardiovascular risk factor.

Conditions

  • Fetal Growth Restriction
  • Cardiac Remodeling, Ventricular
  • Placental Insufficiency
  • Air Pollution

Interventions

OTHER

sample collection

blood sample at 21 weeks of gestation clips of the fetal heart at 21 weeks of gestation, 30 weeks of gestation and 1-3 days after birth collection of umbilical cord blood at birth collection of the placenta at birth

Sponsors & Collaborators

  • KU Leuven

    collaborator OTHER

  • Maxima Medical Center

    collaborator OTHER

  • Hasselt University

    collaborator OTHER

  • University Hospital, Ghent

    lead OTHER

Principal Investigators

  • Kristien Roelens · University Hospital, Ghent

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-22
Primary Completion
2027-02-01
Completion
2028-02-01

Countries

  • Belgium
  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05423665 on ClinicalTrials.gov